News 8 On Your Side is investigating a critical drug shortage frustrating diabetics who need the medicine.Investigator Susan Shapiro looked into the shortage and what the drug maker had to say about ...

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies ...

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...

Eli Lilly on Sunday launched a DTC campaign for its injectable diabetes drug Trulicity as it seeks to build market share in the competitive GLP-1 receptor agonist class, which has four other approved ...

As weight-loss patients and people with type 2 diabetes compete for two popular drugs that are in short supply, federal Health Minister Mark Butler has acknowledged it is a "very challenging" ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.

Eli Lilly’s diabetes drugs Mounjaro and Trulicity are in short supply due to heightened demand for the medication, the Food and Drug Administration (FDA) announced recently. Pharmacies are ...

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...

(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with ...

Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in ...